Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinnaining Capsule (also commonly transliterated as Xinnaoning Capsule) is a traditional Chinese patent medicine (CPM) formulated from five active herbal ingredients: *Ginkgo biloba* L. (Ginkgo Leaf), *Buxus sinica* var. *parvifolia* (Boxwood Leaf), *Salvia miltiorrhiza* Bunge (Danshen), *Cinnamomum migao* H.W. Li (Fructus Cinnamomum migao), and *Allium macrostemon* Bunge (Longstamen Onion Bulb). It is developed and manufactured by Guizhou Jingcheng Pharmaceutical, a subsidiary of Jingfeng Pharmaceutical (which is controlled by CSPC Pharmaceutical Group). Xinnaining Capsule is indicated for promoting Qi and blood circulation, resolving blood stasis, and relieving pain. It is widely prescribed in China for the treatment of cardiovascular and cerebrovascular diseases, including coronary heart disease, chronic stable angina pectoris, acute coronary syndrome (ACS), cerebral arteriosclerosis, and carotid artery plaque.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinnaining Capsule.